Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the production of short chain fatty acids (fatty acids are part of your diet) in stool through the measurement of fecal inulin after a one-time ingestion of 10-gram dose of inulin among healthy adult volunteers.


Clinical Trial Description

The Study involves 2 visits and will include 3 types of subjects. Any healthy adult between the ages of 18 and 75 with no prior history of GI disease or symptoms is eligible to participate in the study. Visit 1 (Day 1) - Screening Visit and Informed Consent At this Visit volunteers will do the following - Volunteers will be asked to read and sign the informed consent after all questions about the study have been answered. This is a screening visit, and we may determine that the volunteers ineligible to continue to participate in the study. - Volunteers will have medical history taken including demographics, symptoms and history of illness. - Volunteers will be asked about the medications. - A physical exam will be performed by the physician. - Vital signs will be measured. - Volunteers will be scheduled for study-days and will fill out a bowel disease questionnaire (BDQ). - Volunteers will be provided instructions for collection, storage, and transportation of stool for your next visit. - Volunteers will be provided a kit for stool collection, storage, and transportation. - Volunteers will be provided a bowel pattern diary to record bowel symptoms over the course of the study. - Volunteers will also be provided with 10-gram inulin powder supplement and will be required to consume the inulin before 9 am on Day 2. Day 2 (at home): - Day 2 reflects the first day of active study. Day 2 may occur anytime up to 30 days after Day 1. This will depend whether the volunteers need to stop any medications or on the day they are able to return for the final visit. - Volunteers will have to consume the inulin supplement before 9 am on Day 2. The first 24-hour stool collection will begin starting at 7 am on Day 2 and will continue until 7 am on Day 3. - All collected stool should be stored as per instructions provided on Day 1 (screening visit). - Volunteers will be asked to record bowel symptoms using the bowel diary card and dietary intake data for four days from Day 2 through Day 5 by using diaries (diet information may be recorded using either the paper diaries that are provided or the web-based Automated Self-Administered Dietary Assessment Tool (https://epi.grants.cancer.gov/asa24/). Day 3 to 4 (at home) - The second 24-hour stool collection will begin starting at 7 am on Day 3 and continue until 7 am Day 4. Volunteers will record the diet for Day 3 to 4 as "Day 3 Diet" and will record bowel symptoms using a Bowel Diary Card. Day 4 to 5 (at home)- Volunteers will start third 24-hour stool collection at 7 am on Day 4 and continue until 7 am Day 5. The diet for Day 4 to 5 should be recorded as "Day 4 Diet." Volunteers will record the bowel symptoms using a Bowel Diary Card. Day 5 to 6 (at home)- The fourth 24-hour stool collection begins at 7 am on Day 5 and continue until 7 am Day 6. Volunteers will record the diet for Day 5 to 6 as "Day 5 Diet" and will record bowel symptoms using a Bowel Diary Card. Visit 2 (Day 6) - End of study: Volunteers will return the refrigerated stool specimens, bowel diaries and dietary intake diaries to the study team. Diaries may also be returned by mail, fax, or by electronic submission. For the diet diaries, volunteers will have the option to complete paper diaries or the Automated Self-Administered Dietary Assessment. Volunteers' participation in the study will end after this visit. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05254340
Study type Interventional
Source Indiana University
Contact
Status Terminated
Phase N/A
Start date August 1, 2021
Completion date July 31, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1